Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.
Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride.
The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients.
A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OPN, IL-17, and RORγt responses and by increasing IL-10 production in experimental allergic encephalomyelitis.
Astrocyte-derived lactosylceramide implicated in multiple sclerosis.
Receptos doses first patient in Phase 2/3 trial for RPC1063 in multiple sclerosis
Refining diagnosis of multiple sclerosis with revised MRI criteria.
Gpr126 is essential for peripheral nerve development and myelination in mammals.
Long term safety and efficacy study of teriflunomide 7 mg or 14 mg in patients with relapsing-remitting multiple sclerosis
Cladribine exerts an immunomodulatory effect on human and murine dendritic cells.
The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.
Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)
Oracle Cladribine in Early Multiple Sclerisis (MS) (ORACLE MS)
Chemotherapeutics in the treatment of multiple sclerosis.
Chemotactic Cytokines: Gordon Research Conference on Molecular and Cellular Mechanisms in Health and Disease
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
Once-daily AUBAGIO® delayed onset of clinically definite multiple sclerosis (MS) in TOPIC study
Determination and characterization of a cannabinoid receptor in rat brain.
IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci.
Chronic cladribine administration increases amyloid Beta Peptide generation and plaque burden in mice.
Intas launches biosimilar version of Rituximab
Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.

Pages